诺诚健华（香港联交所代码：09969）是一家商业化阶段的生物医药高科技公司，专注于恶性肿瘤及自身免疫性疾病治疗领域的一类新药研制，适用于中国病人高发的淋巴瘤、肝癌、胆管癌、尿路上皮癌等多种恶性肿瘤及自身免疫性疾病。现有多个新药产品处于商业化、临床及临床前研发阶段。公司在北京、南京、上海、广州、美国新泽西和波士顿均设有分支机构。<\/p> \n

\n \n \n \n \n \n \n \n
联系人<\/b><\/span><\/p> <\/td> \n

<\/td> \n <\/tr> \n
媒体<\/b><\/span><\/p> <\/td> \n
投资者<\/b><\/span><\/p> <\/td> \n <\/tr> \n
陆春华<\/span><\/p> <\/td> \n

<\/td> \n <\/tr> \n
86-10-66609879<\/span><\/p> <\/td> \n
86-10-66609999<\/span><\/p> <\/td> \n <\/tr> \n
chunhua.lu@innocarepharma.com<\/a><\/span><\/p> <\/td> \n
ir@innocarepharma.com<\/a><\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p>"]; $("#dvExtra").html(content_array[0]);})();

联系人<\/b><\/span><\/p> <\/td> \n	<\/td> \n <\/tr> \n
媒体<\/b><\/span><\/p> <\/td> \n	投资者<\/b><\/span><\/p> <\/td> \n <\/tr> \n
陆春华<\/span><\/p> <\/td> \n	<\/td> \n <\/tr> \n
86-10-66609879<\/span><\/p> <\/td> \n	86-10-66609999<\/span><\/p> <\/td> \n <\/tr> \n
chunhua.lu@innocarepharma.com<\/a><\/span><\/p> <\/td> \n	ir@innocarepharma.com<\/a><\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n <\/p>"]; $("#dvExtra").html(content_array[0]);})();